Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8165110 | 0.94 | DDB1 (0.34) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL8278256 | 0.93 | REN (0.33) | ADRB3ADRA2BADRA2C | |
| SCHEMBL13886148 | 0.93 | REN (0.33) | ADRB3ADRA2BADRA2C | |
| SCHEMBL8294160 | 0.89 | DRD2 (0.35) | ADRB3ADRA2BADRA2C | |
| SCHEMBL13896342 | 0.88 | SCN9A (0.32) | ADRB3ADRA2BADRA2CSCN9A | |
| SCHEMBL8376931 | 0.88 | ADRB3 (0.37) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL7882981 | 0.87 | ADRB3 (0.37) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL3369231 | 0.86 | ADRB3 (0.41) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL17970111 | 0.86 | ADRB3 (0.44) | DDB1CRBNADRB3ADRA2BADRA2C | |
| SCHEMBL498004 | 0.86 | ADRB3 (0.44) | DDB1CRBNADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305695-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305697-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305696-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2305698-A2 | Macrocyclic inhibitors of Hepatitis C virus replication | Intermune, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |